RXi Pharmaceuticals (Nasdaq: RXII) 38.3% LOWER; presenting at the Rodman & Renshaw 16th Annual Global Investment Conference today. In part, the company said interim data
for first Phase 2a trial RXI-109-1301 of lower abdominal hypertrophic scars showed that